Susan Drapeau, PhD
Susan Drapeau, Ph.D. joined Sigilon Therapeutics in 2019 with over 20 years of industry experience in cell therapy, biologics, biomaterials, protein therapies and medical device development. Previously, she served as the Senior Director of Business Development and Strategy at Vericel Corporation, where she evaluated new technologies and supported MACI and Epicel, two FDA approved autologous cellular therapies. Prior to Vericel, Dr. Drapeau spent 14 years at Medtronic Spine running part of the biologics product development organization as well as leading due diligence efforts in business development. While at Medtronic, her team launched five products, gained many 510(k) approvals, submitted several INDs and supported manufacturing, tech transfer, due diligence and intellectual property. Prior to Medtronic, Dr. Drapeau ran the bone product development team at Osiris Therapeutics, focusing on allogeneic cell therapies in combination with biomaterials. During her career Dr. Drapeau has worked in orthopedics, cardiac, burn, dental and pain therapies.
In addition to industry experience, Dr. Drapeau serves as an advocate for the biomedical field currently as a Director and previously as the Industry Chair of the American Institute of Medical and Biological Engineering. She also serves on the Advisory Board for UCSF Tissue Engineering Consortium Grant. Dr. Drapeau holds B.S. degrees in chemical engineering and chemistry from Purdue University and a Ph.D. in chemical engineering from Rice University. She is an inventor on 60 patents and a co-author of 90 journal articles, book chapters and presentations.